PCN Insights, News, Videos, and More

The US Food and Drug Administration has approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults, maker Supernus Pharmaceuticals recently...

While people with borderline intellectual impairment showed increasing prevalence of several mental health disorders over a decade and a half, access to formal psychiatric care did not increase, according to a study published in the Journal...

An adolescent anxiety disorder treatment program that combines group cognitive behavioral therapy (CBT) with high degrees of exposure practice, including family and school involvement, is showing superior results compared to other studied...

FDA Psychopharmacologic Drugs Advisory Committee (PDAC) voted 9 to 3 that there is not sufficient evidence pimavanserin is effective in the treatment of hallucinations and delusions associated with Alzheimer disease psychosis.

The Toronto-based company’s CYB003 becomes the first novel psilocybin analog to enter clinical development.

The Department of Veterans Affairs (VA) has begun offering psychedelic substances to clinical trial patients, according to a recent report in the New York Times.

Numerous chances for care providers to identify alcohol misuse going unnoticed, researchers say.

Patients with chronic migraine, as compared to episodic migraine, displayed higher rates of comorbid sleep disorders, including obstructive sleep apnea (OSA) and insomnia.